Barclays PLC Has $923,000 Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Barclays PLC decreased its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 7.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 127,789 shares of the biopharmaceutical company’s stock after selling 10,829 shares during the period. Barclays PLC owned about 0.21% of Sage Therapeutics worth $923,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SAGE. Headlands Technologies LLC boosted its holdings in shares of Sage Therapeutics by 245.3% during the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 2,782 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Sage Therapeutics by 66.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 4,672 shares during the last quarter. Creative Planning acquired a new position in shares of Sage Therapeutics in the third quarter valued at approximately $88,000. Quest Partners LLC grew its holdings in Sage Therapeutics by 14.5% during the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock worth $128,000 after acquiring an additional 1,486 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of Sage Therapeutics during the third quarter valued at $146,000. Institutional investors own 99.22% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SAGE. Oppenheimer decreased their price target on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Wednesday, October 30th. Piper Sandler reduced their price objective on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Truist Financial dropped their target price on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, October 30th. Stifel Nicolaus lowered their price objective on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a research report on Monday, December 16th. Finally, HC Wainwright restated a “neutral” rating and set a $14.00 target price on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Three equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $10.53.

Sage Therapeutics Stock Down 0.8 %

NASDAQ SAGE opened at $7.44 on Wednesday. The firm has a market cap of $455.13 million, a P/E ratio of -1.33 and a beta of 0.91. The company’s 50 day moving average is $5.64 and its 200-day moving average is $7.53. Sage Therapeutics, Inc. has a 12-month low of $4.62 and a 12-month high of $27.67.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The company had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. During the same period in the previous year, the business earned ($2.81) earnings per share. Sage Therapeutics’s revenue was up 337.1% on a year-over-year basis. Equities analysts expect that Sage Therapeutics, Inc. will post -6.53 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.